
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Corporation (MCK) faces mixed Q3 2025 results, but strategic growth in pharmaceuticals and RxTS offers a promising outlook. Dividend declared.
A comprehensive analysis of McKesson Corporation (MCK), including Q3 earnings, strategic initiatives, analyst estimates, and macroeconomic factors. A balanced outlook for investors.
McKesson's Q3 2025 earnings reveal a mixed performance amid macroeconomic challenges. Strategic initiatives and investor sentiment shape the future outlook.
McKesson's Q3 Fiscal 2025 results present a mixed picture: EPS beats expectations, but revenue falls short, prompting a deeper look into strategic moves and market dynamics.
McKesson's Q3 2025 reveals mixed performance with EPS beat but revenue miss. Focus shifts to strategic initiatives and market adaptation.
McKesson’s Q3 2025 earnings surpassed EPS targets despite a revenue miss, highlighting segmented growth and evolving market challenges.
McKesson Corporation's latest news: Q3 earnings analysis, strategic shifts, and market impact. Stay informed with real-time data and expert insights.